Depomed Reports Positive Parkinson's Drug Study Results

Depomed has completed the second Phase I trial of DM-1992. DM-1992 was well-tolerated in the study.

Specialty pharmaceutical company Depomed has announced positive results from the second Phase I trial of DM-1992, its investigative gastric-retentive, extended-release formulation of levodopa / carbidopa in patients with Parkinson's disease.

The study demonstrated that two distinct twice-daily formulations of DM-1992 maintained therapeutic blood levels of levodopa over 24 hours.

Both the formulations are projected, at steady state, to consistently maintain levodopa blood levels above the efficacious threshold of 300ng/mL for 24 hours, as mean levodopa blood levels after 24 hours were above 300ng/mL.

DM-1992 was well-tolerated in the study.